Management of Heart Failure With Preserved Ejection Fraction: 2026 ACC Expert Consensus Decision Pathway
Authors, Journal, Affiliations, Type, DOI
- Michelle M. Kittleson (Chair), Gurusher S. Panjrath (Vice Chair), Khadijah K. Breathett, Dave L. Dixon, James L. Januzzi Jr, Selma F. Mohammed, Katie Bates; American College of Cardiology Solution Set Oversight Committee.
- Journal of the American College of Cardiology, 2026;88(15):1817-1846 (October 13, 2026 issue).
- Type: ACC expert consensus decision pathway, updating the 2023 HFpEF ECDP.
- DOI: 10.1016/j.jacc.2026.06.018.
- Approved by the ACC Clinical Policy Approval Committee in July 2026.
Overview
The 2026 ACC expert consensus decision pathway updates the 2023 document for the diagnosis and management of HFpEF. It organizes care into three steps: identify possible HFpEF from symptoms and signs, exclude noncardiac and cardiac mimics, and implement optimal medical therapy alongside nonpharmacologic management and comorbidity control. The central therapeutic change is the establishment of an SGLT2 inhibitor plus a nonsteroidal mineralocorticoid receptor antagonist as foundational therapy, with incretin-based therapy for obesity-phenotype HFpEF, ARNI for selected patients, and ARB when ARNI is not feasible. The pathway also emphasizes diagnostic scoring systems, the limitations of natriuretic peptides in obesity, and the cardiovascular-kidney-metabolic framework.
Keywords
HFpEF, expert consensus decision pathway, SGLT2 inhibitors, finerenone, mineralocorticoid receptor antagonists, semaglutide, tirzepatide, ARNI, obesity, cardiovascular-kidney-metabolic syndrome
Key Takeaways
Introduction
- HFpEF accounts for more than 50% of heart failure and has outcomes comparable to HFrEF; its incidence continues to rise.
- The conceptual framework has shifted from diastolic dysfunction alone to a multisystem syndrome driven by visceral adiposity, inflammatory adipokines and metabolic dysfunction.
- Recent trials of SGLT2 inhibitors, nonsteroidal MRAs and incretin-based therapies prompted the update.
Assumptions and Definitions
- The document focuses on ambulatory HFpEF and does not supersede clinical judgment.
- Guideline-directed medical therapy means treatments supported by clinical practice guidelines; optimal medical therapy may include therapies with demonstrated benefit in emerging trials not yet reflected in guidelines.
- HFpEF mimics are defined as a clinical HF diagnosis with LVEF ≥50% and a primary noncardiac cause (pulmonary, kidney, liver disease, obesity, frailty) or an underlying cardiac cause (infiltrative or hypertrophic cardiomyopathy, valvular disease, pericardial disease, high-output HF) with distinct pathophysiology and therapeutic implications.
Diagnosis
- No single test establishes HFpEF: the echocardiogram is not pathognomonic and natriuretic peptides may be normal, especially in obesity.
- Differential diagnosis of dyspnea is organized by cardiac, pulmonary and other causes; edema is organized by increased hydrostatic pressure versus decreased oncotic pressure.
- Three diagnostic scores are available: H2FPEF, HFA-PEFF and HFpEF-ABA.
- H2FPEF is more sensitive and may be more useful in clinical practice; HFA-PEFF is more specific but more complex, often requiring diastolic stress testing or invasive hemodynamics.
- HFpEF-ABA uses age, body mass index and atrial fibrillation and is the easiest to implement in primary care, but requires an online calculator and has no established probability thresholds.
- A reasonable strategy is H2FPEF for initial screening, HFA-PEFF for confirmation, and advanced testing when the two disagree.
- Natriuretic peptide levels are lower in HFpEF than HFrEF and lower in obesity, Black race, women with increased androgenicity and insulin resistance; normal levels do not exclude HFpEF.
HFpEF Mimics
- Noncardiac mimics: pulmonary disease, kidney disease, high-output states (liver disease, anemia, hyperthyroidism, arteriovenous fistula, systemic inflammation), obesity and frailty/deconditioning.
- Cardiac mimics: valvular heart disease (aortic stenosis, mitral regurgitation, mitral stenosis), pericardial constriction, ischemic heart disease and myocardial disease (cardiac amyloidosis, hypertrophic cardiomyopathy, cardiac sarcoidosis, hemochromatosis, Fabry disease).
- A stepwise approach excludes noncardiac mimics first, then cardiac mimics; if none is found, HFpEF is diagnosed and comorbidities are identified for management.
Sex-Specific Considerations
- Women have a higher prevalence of HFpEF than HFrEF, are older at diagnosis and have a greater attributable risk from hypertension, type 2 diabetes and obesity.
- Women with HFpEF have smaller LV cavities, lower LV mass, more concentric remodeling, lower natriuretic peptide levels and more impaired exercise capacity than men.
- Unique female risk factors include hypertensive disorders of pregnancy, gestational diabetes, infertility and early menopause.
Optimal Medical Therapy
- SGLT2 inhibitors are the cornerstone of HFpEF therapy, supported by DELIVER and EMPEROR-Preserved; they reduce the combined endpoint of HF hospitalization and cardiovascular death and improve health status, without a demonstrated reduction in cardiovascular death alone.
- Finerenone should be the MRA of choice, on the basis of FINEARTS-HF; spironolactone is a reasonable alternative if cost or tolerance is prohibitive, and eplerenone may be used for gynecomastia.
- Incretin-based therapy with semaglutide or tirzepatide may be used for HFpEF with BMI ≥30 to improve health status and exercise function and potentially reduce worsening HF events; the risk of sarcopenic obesity requires exercise and nutritional support.
- Sacubitril-valsartan may be reasonable in women or patients with LVEF ≤57%, particularly when additional blood pressure control is needed; the PARAGON-HF primary endpoint was not statistically significant.
- ARBs provide a modest reduction in HF hospitalization and are reasonable when ARNI is contraindicated or unaffordable; ACE inhibitors are not a suitable alternative.
- Loop diuretics should be used judiciously for congestion; no beta-blocker benefit has been established, and use should be limited to specific indications such as angina or AF rate control.
- Recommended starting and target doses are provided for dapagliflozin, empagliflozin, sotagliflozin, spironolactone, finerenone, semaglutide, tirzepatide, sacubitril-valsartan and candesartan.
- The pathway recommends early initiation and titration of SGLT2 inhibitor and nonsteroidal MRA unless contraindicated, with incretin therapy for BMI ≥30, ARNI for selected patients and ARB as an alternative.
Nonpharmacologic Management
- Exercise for 3–4 months improves exercise capacity and quality of life, although longer-term benefits are inconsistent; exercise should be encouraged for patient-centered outcomes even without proven reduction in HF hospitalization or death.
- Caloric restriction with or without exercise improves exercise capacity in obesity-related HFpEF, but benefits are not sustained after the intervention stops.
- Implantable pulmonary artery monitors may reduce HF hospitalization in selected patients with recurrent hospitalization, labile volume status, cardiorenal syndrome or diagnostic uncertainty; atrial shunt devices, splanchnic nerve ablation and pacemakers have not shown consistent benefit.
Comorbidities
- Coronary artery disease is present in more than 50% of HFpEF patients and in up to 91% when coronary microvascular dysfunction is included; management follows guideline-directed secondary prevention.
- Atrial fibrillation affects up to 41% of HFpEF patients and is associated with worse symptoms and outcomes; rate control, rhythm control and anticoagulation follow the 2023 ACC/AHA AF guideline, and catheter ablation may be considered for limiting symptoms.
- Hypertension is present in up to 90%; the optimal systolic blood pressure appears to be 120–129 mmHg, with both ≥140 and <120 associated with worse outcomes.
- Chronic kidney disease affects up to 60%; RAS inhibitors, SGLT2 inhibitors, nonsteroidal MRAs and GLP-1 receptor agonists all reduce kidney disease progression.
- Type 2 diabetes affects up to half; SGLT2 inhibitors are foundational regardless of diabetes status, GLP-1 receptor agonists offer additional cardiorenal benefit, and dipeptidyl peptidase-4 inhibitors (saxagliptin, alogliptin) and thiazolidinediones should be avoided.
- Obesity affects up to 80% and contributes to HFpEF through visceral adiposity, inflammation, plasma volume expansion and impaired exercise capacity; treatment requires nutrition, exercise, incretin-based therapy and consideration of bariatric surgery.
- The cardiovascular-kidney-metabolic framework unifies comorbidity management; a single severely uncontrolled cardiometabolic condition confers a 23% increase in all-cause hospitalization risk, and two to three conditions a 57% increase.
Conclusion
- Accurate diagnosis is the prerequisite for evidence-based therapy; the pathway provides practical guidance for implementing current best practice while acknowledging that many questions remain unanswered.
Limitations of the Document
- Expert consensus decision pathway rather than a formal guideline; recommendations are not graded with the same methodology as ACC/AHA guidelines.
- The document focuses on ambulatory care and does not address acute decompensated HFpEF in detail.
- Several recommendations rest on subgroup analyses, post hoc analyses or trials with surrogate endpoints.
- The evidence base for HFpEF remains limited by phenotypic heterogeneity and the absence of a mortality benefit for any pharmacotherapy.
- The pathway does not resolve the choice between finerenone and spironolactone, the role of ARNI in the SGLT2 inhibitor era, or the optimal duration of incretin therapy.
Key Concepts Mentioned
- concepts/HFpEF-Management — the treatment pathway this document updates
- concepts/HFrEF-Management — the contrasting phenotype
- concepts/GLP-1-Receptor-Agonists — incretin-based therapy in obesity-HFpEF
- concepts/SGLT2-Inhibitors-in-CKD — the shared cardiorenal drug class
- concepts/Chronic-Kidney-Disease — a common comorbidity and management target
- concepts/Obesity-Paradox — intentional weight loss in HFpEF
Key Entities Mentioned
- entities/HFpEF — the phenotype, diagnostic scores and mimics
- entities/Heart-Failure — the parent syndrome
- entities/Sacubitril-Valsartan — ARNI evidence and positioning
- entities/Finerenone — the preferred MRA
- entities/Semaglutide — STEP-HFpEF evidence
- entities/Tirzepatide — SUMMIT evidence
- entities/Obesity — the dominant comorbidity
- entities/Atrial-Fibrillation — a common comorbidity
- concepts/Chronic-Kidney-Disease — a common comorbidity
- entities/Type-2-Diabetes — a common comorbidity
Wiki Pages Updated
wiki/sources/HFpEF-ACC-JACC-2026.md— created (this file)wiki/concepts/HFpEF-Management.md— updated with the 2026 ECDP recommendationswiki/entities/HFpEF.md— updated with the diagnostic scoring comparisonwiki/entities/Sacubitril-Valsartan.md— updated with the ECDP positioningwiki/entities/Tirzepatide.md— updated with the ECDP recommendationwiki/entities/Semaglutide.md— updated with the ECDP recommendationwiki/concepts/GLP-1-Receptor-Agonists.md— updated with the HFpEF guidancewiki/wikiindex.md— updatedwiki/sourceindex.md— updated